<DOC>
	<DOC>NCT00851448</DOC>
	<brief_summary>To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and anorexia in lung cancer patients.</brief_summary>
	<brief_title>Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<criteria>nonsmall cell lung cancer patients stage IIIb or IV planned chemotherapy or combined chemo/radiotherapy current body weight less than 6 months ago abnormal CRF level BMI &gt;=20 kg/m2 and &lt;=30kg/m2 significant oedema in the time of screening and randomisation concomitant inflammatory diseases active infections including HIV and AIDS liver failure chronic renal failure or cardiac pacemaker chronic heart failure insulin treated diabetes mellitus medications that impair sex hormone synthesis, secretion or function acute or chronic infections body weight loss &gt; 5% during the last 6 months or &gt; 10% during the last 10 months fish oil supplementation within 3 months prior to study entry taking vitamins in doses greater than recommended daily allowance life expectancy less than 6 months in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>